Sally A Wood1, Adrian C Davis, Graham J Sutton. 1. Newborn Hearing Screening Programme Centre (England), Royal Free London NHS Foundation Trust, London, UK. sally.wood3@nhs.net
Abstract
OBJECTIVE: To examine the effectiveness of targeted surveillance for the identification of moderate-profound PCHI in babies who pass the newborn hearing screen in England and have risk factors. DESIGN: Retrospective analysis. STUDY SAMPLE: 2,307,880 children born 01/04/06-30/09/09 in England. RESULTS: Overall the prevalence for all PCHI in children with risk factors who pass newborn hearing screening is 1.49/1000. The risk factors with the highest prevalence are (1) Syndrome (other than Down's) associated with a hearing loss; (2) NICU with refer in both ears at OAE and pass in both ears at AABR; (3) Craniofacial anomaly; (4) Down's syndrome; (5) Congenital infection. CONCLUSION: Targeted surveillance for children who pass the screen and have the risk factors 1-5 listed above will be retained within the English NHSP; targeted surveillance for children who pass the screen and have other risk factors is not effective and has been discontinued.
OBJECTIVE: To examine the effectiveness of targeted surveillance for the identification of moderate-profound PCHI in babies who pass the newborn hearing screen in England and have risk factors. DESIGN: Retrospective analysis. STUDY SAMPLE: 2,307,880 children born 01/04/06-30/09/09 in England. RESULTS: Overall the prevalence for all PCHI in children with risk factors who pass newborn hearing screening is 1.49/1000. The risk factors with the highest prevalence are (1) Syndrome (other than Down's) associated with a hearing loss; (2) NICU with refer in both ears at OAE and pass in both ears at AABR; (3) Craniofacial anomaly; (4) Down's syndrome; (5) Congenital infection. CONCLUSION: Targeted surveillance for children who pass the screen and have the risk factors 1-5 listed above will be retained within the English NHSP; targeted surveillance for children who pass the screen and have other risk factors is not effective and has been discontinued.